Celldex
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Celldex and other ETFs, options, and stocks.About CLDX
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases.
CEOAnthony S. Marucci
CEOAnthony S. Marucci
Employees186
Employees186
HeadquartersHampton, New Jersey
HeadquartersHampton, New Jersey
Founded1983
Founded1983
Employees186
Employees186
CLDX Key Statistics
Market cap1.78B
Market cap1.78B
Price-Earnings ratio-8.92
Price-Earnings ratio-8.92
Dividend yield—
Dividend yield—
Average volume915.50K
Average volume915.50K
High today$27.01
High today$27.01
Low today$26.03
Low today$26.03
Open price$26.35
Open price$26.35
Volume688.29K
Volume688.29K
52 Week high$29.38
52 Week high$29.38
52 Week low$14.40
52 Week low$14.40
CLDX News
Simply Wall St 3d
Celldex Therapeutics: Assessing Valuation as Barzolvolimab Hype and Biotech Optimism Drive Renewed Investor FocusCelldex Therapeutics (CLDX) has seen renewed interest as excitement builds over barzolvolimab's outlook in chronic urticaria, along with broader positive moment...
TipRanks 5d
Celldex initiated with an Underweight at BarclaysBarclays initiated coverage of Celldex (CLDX) with an Underweight rating and $25 price target The firm launched coverage of eight companies across inflammation...
Analyst ratings
80%
of 15 ratingsBuy
80%
Hold
13.3%
Sell
6.7%
People also own
Based on the portfolios of people who own CLDX. This list is generated using Robinhood data, and it’s not a recommendation.